Aardvark Therapeutics (AARD) Stock: Buy, Sell, or Hold?
AARD - Aardvark Therapeutics, Inc. Common Stock
$1.39
-2.56 (-64.81%)
▼
5d:
-63.23%
30d:
-74.95%
90d:
-79.22%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When AARD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AARD is down 63.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AARD is down 63.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AARD is currently trading at $1.39, which is considered oversold relative to its 30-day fair value range of $3.86 to $5.63.
Technical Outlook: Technically, AARD is showing sideways momentum. The price is currently testing key support at $1.39. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 64.8% recently.
Market Sentiment: AARD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.89 (+683.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AARD is showing sideways momentum. The price is currently testing key support at $1.39. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 64.8% recently.
Market Sentiment: AARD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.89 (+683.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.86 -
$5.63
Company Quality Score
43/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-64.8%)
- BULLISH: Trading 683.4% below Wall St target ($10.89)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.86 -
$5.63
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.39
Resistance Level
$4.88
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.59
Wall Street Target
$10.89
(+683.4%)
Share & Embed Analysis
Last updated: October 24, 2026 5:06 PM ET
Data refreshes hourly during market hours. Next update: 6:06 PM
Data refreshes hourly during market hours. Next update: 6:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AARD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 53 HOLD |
